

Fagron Advanced Derma

Compatibility table

Legend

Compatible combination for

- 14/15 days
- 30 days
- 60 days
- 90 days

★ Especially recommended combination

% Compatible combination up to x%

⊗ Combination not compatible

○ Combination not studied

API/DCI

		Skin types								
		Oily skin	Balanced skin	Dehydrated skin	Very dehydrated skin	Affected skin	Specific skin area			
		Common concentration(s)								
		OCCLUVAN™	EMOLIVAN™	VERSATILE™ RICH	VERSATILE™	NOURIVAN™ ANTIOX	FITALITE™	SERAQUA™	SOLYDRA™	ESPUMIL™
Alfatradiol (17α-estradiol)	0.025 to 0.05%	○	○	○	○	○	●	●	○	●
Aloe vera extract	0.5 to 10%	○	●	●	●	8% ●	5% ●	●	⊗	○
Alpha bisabolol	0.5 to 5%	○	●	●	●	●	●	1% ●	○	○
Ammonium lactate	1 to 12%	○	●	10% ●	10% ●	8% ●	⊗	○	○	○
Anthralkine/dithranol	0.05 to 3%	●	●	●	●	●	○	○	○	○
Arginine HCl	2.5%	○	●	●	●	●	⊗	⊗	○	○
Ascorbic acid (vit. C)	5 to 15%	○	○	●	●	●	⊗	10% ●	○	○
Azelaic acid	10 to 20%	○	⊗	●	●	○	●	⊗	○	○
Benzoyl peroxide	2.5 to 10%	○	○	●	●	⊗	5% ●	○	○	○
Benzyl benzoate	25%	○	●	⊗	●	○	⊗	○	○	○
Betamethasone dipropionate	0.05%	●	●	●	●	●	●	○	○	○
Betamethasone valerate	0.025 to 0.1%	●	●	●	●	●	●	○	○	○
Caffeine	1 to 2%	○	○	●	●	●	●	●	○	●
Chamomile extract	0.5 to 5%	●	●	●	●	●	●	●	⊗	○
Ciclopirox olamine	1%	●	●	●	●	●	●	○	○	○
Clindamycin HCl	1 to 3%	○	○	●	●	○	●	○	○	○
Clobetasol propionate	0.05%	●	●	●	●	●	●	●	○	●
Clotrimazole	1 to 2%	○	●	●	●	○	●	○	○	○
Coal tar crude (pix lithanthracis)	1 to 10%	●	●	●	●	○	○	○	○	○
Coal tar solution (LCD)	5 to 20%	10% ●	●	10% ●	10% ●	○	○	○	○	○
Cyanocobalamin (vit. B12)	0.07%	●	●	●	●	●	●	●	○	○
Desonide	0.05 to 0.1%	●	●	●	●	●	●	○	○	○
Desoximetasone	0.25%	●	●	●	●	●	●	○	○	○
Dexpanthenol	0.5 to 5%	●	●	●	●	●	●	●	⊗	○
Diclofenac sodium	3%	○	●	●	●	○	⊗	●	○	○
Diffucortolone valerate	0.1 to 0.3%	●	●	●	●	●	●	○	○	○
Erythromycin	0.5 to 4%	○	○	●	●	●	●	○	○	○
Finasteride	0.1%	○	○	○	○	○	○	●	○	●
Fluocinonide acetonide	0.01 to 0.1%	●	●	●	●	●	●	○	○	○
Glycerol	0.5 to 20%	●	●	●	●	8% ●	5% ●	●	○	○
Glycolic acid	5 to 15%	○	○	●	●	●	●	●	○	○
Hyaluronic acid	0.2 to 2.5%	●	⊗	⊗	⊗	○	⊗	⊗	○	○
Hydrocortisone	0.25 to 2.5%	●	●	●	●	●	●	○	○	○
Hydrocortisone acetate	0.25 to 2.5%	●	●	●	●	●	●	○	○	○
Hydroquinone	2 to 10%	○	○	⊗	⊗	★	⊗	⊗	○	○
Ketoconazole	2%	○	●	●	●	○	●	●	○	●
Kojic acid	1 to 4%	○	○	○	○	●	●	●	○	○
Lactic acid	1 to 20%	○	10% ●	●	●	○	●	●	○	○
Latanoprost	0.005%	○	○	○	○	○	●	120 days	○	●
Lidocaine	0.5 to 10%	5% ●	○	○	○	○	○	○	○	○
Lidocaine HCl	0.5 to 5%	⊗	5% ●	●	●	●	⊗	●	○	○
Melatonin	0.0033 to 0.1%	○	○	○	○	○	●	●	○	●
Menthol	1 to 3%	●	●	●	●	●	●	●	0.33% ●	●
Metronidazole	0.5 to 3%	○	○	●	●	⊗	●	●	○	○
Minoxidil	2 to 5%	○	○	○	○	○	●	●	○	180 days
Mometasone furoate	0.1%	●	●	●	●	●	●	○	○	○
Nicotinamide (vit. B3)	2 to 5%	●	●	●	●	●	●	●	⊗	○
Permethrin	5 to 15%	○	●	●	○	○	●	○	○	○
Prostaquinon™	3%	○	○	○	○	○	○	○	○	3% ●
Resorcinol	15%	○	○	⊗	⊗	★	⊗	○	○	○
Retinol (vit. A)	0.4%	○	○	●	●	●	●	●	○	○
Salicylic acid	0.5 to 20%	●	●	10% ●	10% ●	○	5% ●	○	○	○
Shea butter	1 to 20%	●	●	⊗	●	8% ●	5% ●	⊗	⊗	○
Sodium hyaluronate	1%	○	○	○	○	●	○	●	○	○
Sulfur	5 to 10%	●	●	●	●	8% ●	5% ●	○	○	○
Tacrolimus	0.03 to 0.5%	●	●	●	●	●	●	○	○	○
Tetracycline HCl	2 to 3%	○	○	●	●	●	⊗	○	○	○
Tocopherol (vit. E)	0.5 to 20%	●	●	●	●	8% ●	5% ●	●	○	○
Tretinoin (vit. A acid)	0.01 to 0.1%	○	○	●	●	●	●	●	○	●
Triamcinolone acetonide	0.025 to 0.1%	●	●	●	●	●	●	○	○	○
Urea	5 to 40%	⊗	10% ●	●	●	○	●	●	⊗	○
Zinc oxide	1 to 40%	●	●	25% ●	10% ●	8% ●	5% ●	○	○	○
Zinc sulfate	1 to 10%	●	●	●	●	8% ●	5% ●	⊗	○	○

Please refer to the Compounding Matters formulations database at fagron.gr for all compounding methods and storage conditions.

Fagron Advanced Derma vehicles allow for stable preparations with a broad range of APIs and DCIs. Combinations that have been scientifically studied for chemical, physical and microbiological stability are included in this Fagron Advanced Derma compatibility table.

The compatibility table and Fagron's free Compounding Matters formulations database support health professionals in exploring possible treatment options. APIs or DCIs that are not included in these resources can also form elegant, stable compounded preparations that help to improve patient comfort and compliance. When no study data is available for a specific API or DCI, it is recommended that the pharmacist assigns an appropriate expiry date based on internal protocols, risk analysis or guidelines from accredited pharmacopoeias.

Disclaimer: While a great deal of effort has been spent to ensure the accuracy of the formulations contained herein, no claims are made as to the uses, safety, efficacy or bioavailability of these recommendations. The content of this table cannot be construed as (medical) advice, recommendation or opinion. Medical professionals, doctors and compounding pharmacists using this information are advised to do so solely if appropriate in their own professional opinion and judgement. Fagron does not accept and cannot be held responsible or liable in any case for the formulations or information contained herein.

FADct08 / 20190227



T +30 24310 83633-5
F +30 24310 83615
www.fagron.gr

Fagron Hellas
12 km N.R. Titkalia - Larisa
P.O. Box 32
Titkalia, Greece

